TAAR1 and Alzheimer disease: Notably, in a very recent work Accorroni et al. demonstrated that in the same experimental model co-administration of 5 nM EPPTB, a selective TAAR1 antagonist, was able to revert the rescuing effects of T1AM on LTP [35], suggesting a role of TAAR1 as a possible drug target to ameliorate cognitive dysfunction in AD patients.